Biology Reference
In-Depth Information
Ganeshan S, Dickover RE, Korber BT, Bryson YJ, Wolinsky SM. 1997. Human immunode®ciency
virus type 1 genetic evolution in children with di¨erent rates of development of disease. J Virol
71: 663±677.
Goodenow M, Huet T, Saurin W, Kwok S, Sninsky J, Wain-Hobson S. 1989. HIV-1 isolates are
rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions.
J Acquired Immune De®c Syndr 2: 344±352.
Hahn BH, Shaw GM, Taylor ME, Red®eld RR, Markham PD, Salahuddin SZ, Wong-Staal F,
Gallo RC, Parks ES, Parks WP. 1996. Genetic variation in HTLV III/LAV over time in patients
with AIDS or at risk for AIDS. Science 232: 1548±1553.
Ho DD, Neuman AU, Perelson AS, Chen W, Leonard JM, Markowitz M. 1995. Rapid turnover of
plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123±126.
Holmes EC, Zhang LQ, Simmonds P, Ludlam CA, Leigh-Brown AJ. 1992. Convergent and diver-
gent sequence evolution in the surface glycoprotein of human immunode®ciency virus type 1
within a single infected patient. Proc Natl Acad Sci USA 89: 4835±4839.
Hu WS, Temin HM. 1990. Genetic consequences of packaging two RNA genomes in one retroviral
particle: pseudodiploidy and a high rate of genetic recombination. Proc Natl Acad Sci USA 87:
1556±1560.
Isaka Y, Sato A, Miki S, Kawauchi S, Sakaida H, Hori T, Uchiyama T, Adachi A, Hayami M,
Fujiwara T, Yoshie O. 1999. Small amino acid changes in the V3 loop of human immuno-
de®ciency virus type 2 determines the coreceptor usage for CXCR4 and CCR5. Virology 264:
237±243.
Kwong PD, Wyatt R, Sattentau QJ, Sodroski J, Hendrickson WA. 2000. Oligomeric modeling and
electrostatic analysis of the gp120 envelope glycoprotein of human immunode®ciency virus. J
Virol 74: 1961±1972.
Kypr J, Mrazek J, Reich J. 1989. Nucleotide composition bias and CpG dinucletide content in the
genomes of HIV and HTLV 1/2. Biochim Biopys Acta 1009: 280.
LaBranche CC, Ho¨man TL, Romano J, Haggarty BS, Edwards TG, Matthews TJ, Doms
RW, Hoxie JA. 1999. Determinants of CD4 independence for a human immunode®ciency
virus type 1 variant map outside regions required for coreceptor speci®city. J Virol 73: 10310±
10319.
Leigh-Brown AJ. 1991. Sequence variability of human immunode®ciency viruses: pattern and pro-
cess in viral evolution. AIDS 5S: 35±42.
Mansky LM, Temin HM. 1995. Lower in vivo mutation rate of human immunode®ciency type 1
than that predicted from the ®delity of puri®ed reverse transcriptase. J Virol 69: 5087±5094.
McNearney T, Hornickowa Z, Markham R, Birdwell A, Arens M, Saah A, Ratner L. 1992. Rela-
tionship of human immunode®ciency virus type 1 sequence heterogeneity to stage of disease.
Proc Natl Acad Sci USA 89: 10247±10251.
Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. 1996. Prognosis in HIV
infection predicted by the quality of virus in plasma. Science 272: 1167±1170.
Menzo S, Sampaolesi R, Vicenzi E, Santagostino E, Liuzzi G, Chirianni A, Piazza M, Cohen OJ,
Bagnarelli P, Clementi M. 1998. Rare mutations in a domain crucial for V3-loop structure pre-
vail in replicating HIV from long-term non-progressors. AIDS 12: 985±997.
Meyerans A, Cheynier R, Albert J, Seth M, Kwok S, Sninsky J, Morfeldt-Manson L, Asjo B,
Wain-Hobson S. 1989. Temporal ¯uctuations in HIV quasispecies in vivo are not re¯ected by
sequential HIV isolations. Cell 58: 901±910.
Murakami T, Zhang TY, Koyanagi Y, Tanaka Y, Kim J, Suzuki Y, Minoguchi S, Tamamura H,
Waki M, Matsumoto A, Fujii N, Shida H, Hoxie JA, Peiper SC, Yamamoto N. 1999. Inhibi-
tory mechanism of the CXCR4 antagonist T22 against human immunode®ciency virus type 1
infection. J Virol 73: 7489±7496.
Myers G. 1994. HIV: between past and future. AIDS Res Hum Retroviruses 10: 1317±1324.
